Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.61 |
| ▸ | DGKA | P23743 | 2/20 | 0.61 |
| ▸ | MGLL | Q99685 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | CNR1 | P21554 | 1/20 | 0.58 |
| ▸ | CNR2 | P34972 | 1/20 | 0.58 |
| ▸ | FAAH | O00519 | 1/20 | 0.55 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.55 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.55 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.55 |
| ▸ | PRKCA | P17252 | 1/20 | 0.55 |
| ▸ | GMNN | O75496 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12179613 | 1.00 | EPHX2 (0.61) | EPHX2DGKAMGLLMAPTALDH1A1 | |
| SCHEMBL18209370 | 0.98 | EPHX2 (0.60) | EPHX2DGKAMGLLMAPTALDH1A1 | |
| SCHEMBL12232837 | 0.98 | EPHX2 (0.60) | EPHX2DGKAMGLLMAPTALDH1A1 | |
| Bromide SCHEMBL20185959 | 0.97 | EPHX2 (0.58) | EPHX2DGKAMGLLMAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL20185950 | 0.97 | EPHX2 (0.58) | EPHX2DGKAMGLLMAPTALDH1A1 | |
| SCHEMBL17586415 | 0.97 | EPHX2 (0.57) | EPHX2DGKAMGLLMAPTALDH1A1 | |
| SCHEMBL14759657 | 0.96 | MGLL (0.68) | EPHX2DGKAMGLLMAPTALDH1A1 | |
| SCHEMBL12179602 | 0.96 | MGLL (0.68) | EPHX2DGKAMGLLMAPTALDH1A1 | |
| SCHEMBL6072564 | 0.94 | CNR2 (0.64) | EPHX2DGKAMGLLMAPTALDH1A1 | |
| SCHEMBL6072553 | 0.94 | CNR2 (0.64) | EPHX2DGKAMGLLMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2567951-B1 | CATIONIC LIPID | KYOWA HAKKO KIRIN CO LTD (JP) | 2018-09-19 | — | — | EP | disclosed |
| EP-3301086-A1 | PRODUCTION OF A COMPOSITION CONTAINING A COMPLEX BETWEEN A MEMBRANE COMPOSED OF A LIPID MONOLAYER AND A NUCLEIC ACID, AND, A LIPID MEMBRANE FOR ENCAPSULATING THE COMPLEX THEREIN | Kyowa Hakko Kirin Co., Ltd. (JP) | 2018-04-04 | — | — | EP | disclosed |
| US-9920028-B2 | Cationic lipid | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2018-03-20 | — | — | US | disclosed |
| US-9845306-B2 | Cationic lipid | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-12-19 | — | — | US | disclosed |
| US-20170349532-A1 | CATIONIC LIPID | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-12-07 | — | — | US | disclosed |
| US-20160304487-A1 | CATIONIC LIPID | KYOWA HAKKO KIRIN CO LTD (JP) | 2016-10-20 | — | — | US | disclosed |
| US-9408914-B2 | Cationic lipid | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2016-08-09 | — | — | US | disclosed |
| US-20150343062-A1 | CATIONIC LIPID | KYOWA HAKKO KIRIN CO LTD (JP) | 2015-12-03 | — | — | US | disclosed |
| EP-2774912-A1 | CATIONIC LIPID | Kyowa Hakko Kirin Co., Ltd. (JP) | 2014-09-10 | — | — | EP | disclosed |
| US-20130280305-A1 | CATIONIC LIPID | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2013-10-24 | — | — | US | disclosed |
| US-20130108685-A1 | CATIONIC LIPID | KYOWA KIRIN CO., LTD. (JP) | 2013-05-02 | — | — | US | disclosed |
| EP-2567951-A1 | CATIONIC LIPID | Kyowa Hakko Kirin Co., Ltd. (JP) | 2013-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304487-A1 | CATIONIC LIPID | LPAR3, ACOX3, H1-3 | EPHX2 1730/4885DGKA 2516/4885MGLL 80/4885 |
| US-20170349532-A1 | CATIONIC LIPID | LPAR3, ACOX3, H1-3 | EPHX2 1730/4885DGKA 2516/4885MGLL 80/4885 |
| US-20130108685-A1 | CATIONIC LIPID | LPAR3, ACOX3, H1-3 | EPHX2 1730/4885DGKA 2516/4885MGLL 80/4885 |
| US-20130280305-A1 | CATIONIC LIPID | LPAR3, ACOX3, H1-3 | EPHX2 1730/4885DGKA 2516/4885MGLL 80/4885 |
| US-20150343062-A1 | CATIONIC LIPID | ACOX3, LPAR3, ELOVL3 | EPHX2 2056/4885DGKA 2367/4885MGLL 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.